This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Peripheral Vascular Disease
and you are
between 18 and 45
years old
Phase
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

Unifusol (R) is a solution of arginine sodium succinate for intravenous infusions. Its effects include vasodilation, protection of inner layer of blood vessels and improvement of blood viscosity. The present phase I study is aimed to evaluate the safety and tolerability of Unifusol infusions in healthy volunteers.

Provided treatments

  • Drug: arginine sodium succinate
Tris trial is registered with FDA with number: NCT03028285. The sponsor of the trial is Scientific Technological Pharmaceutical Firm Polysan, Ltd. and it is looking for 48 volunteers for the current phase.
Official trial title:
Open Randomized Study of the Safety, Tolerability, and Pharmacokinetic Parameters of UNIFUZOL® (Solution for Infusions, 1.4%, Manufactured by "NTFF"POLYSAN " Ltd.,Russia) in Healthy Volunteers at Different Rates of Administration (Phase I)